Bristol Myers Squibb stock edges lower as options activity and new price targets test 2026 guidance
Published on 09/11/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) was recently quoted around USD 64.17 on the New York Stock Exchange as of September 11, 2026, after closing at USD 63.75 with a 1.02 percent decline on September 10, 2026, a move that keeps the shares trading just below an average analyst price target of about USD 66.33.
Guidance and valuation set the tone
According to Ad-hoc-news on September 11, 2026, Bristol Myers Squibb has full-year 2026 earnings guidance of USD 6.75 to USD 7.00 per share, while analysts currently expect about USD 6.95 per share for the year, underscoring that the guidance range is slightly above the midpoint of consensus.
Based on this guidance and current share price levels, Zacks reported on September 10, 2026 that Bristol Myers Squibb shares are up 19.4 percent year to date, compared with 6.3 percent growth for its industry, and trade at 9.81 times forward earnings versus the company’s historical mean of 8.68 and around 18.02 for the large-cap pharma industry, indicating a valuation premium to its own history but still a discount to broader peers.
The same Zacks overview notes that the Zacks Consensus Estimate for 2026 earnings per share has risen from USD 6.32 to USD 6.86 over the past 60 days, while the 2027 estimate moved from USD 6.09 to USD 6.44, a trend that suggests analysts have become more optimistic about Bristol Myers Squibb’s medium-term earnings trajectory even as they keep the stock at a Hold rating.
Analyst price targets cluster near current levels
Analyst opinions around Bristol Myers Squibb stock have converged toward a moderate upside profile in early September 2026. According to MarketBeat as of September 11, 2026, the consensus analyst price target stands at USD 66.33, only about 3.4 percent above the recent quote near USD 64.17, and the stock carries a Moderate Buy rating with an average rating score of 2.56 based on one strong buy, thirteen buy, ten hold and one sell rating.
Drilling down into individual calls, HSBC recently maintained a Hold rating on Bristol Myers Squibb and raised its price target from USD 60.00 to USD 65.00, an 8.33 percent increase that moves the house’s view closer to the broader consensus band, as reported by GuruFocus on September 10, 2026.
On the same day, Scotiabank analyst Louise Chen also maintained a Hold rating and set a price target of USD 60.00, with the average Street price target cited at USD 66.94, according to The Globe and Mail on September 10, 2026.
A separate analyst update summarized by The Globe and Mail on September 10, 2026 notes that BMO Capital’s Evan Seigerman maintains a Hold rating with a USD 60.00 price target, while RBC Capital also keeps a Hold stance with a USD 64.00 target, and reiterates an average price target of USD 66.94, representing an indicated upside of about 3.7 percent from a closing price of USD 64.45 at the time.
For investors, the key takeaway is that most recent price targets sit in a relatively tight band between USD 60.00 and USD 75.00, with the consensus clustering in the mid-USD 60s, so the current share price near USD 64.00 already reflects a large portion of the expected fundamental improvement implied by the rising earnings estimates.
Options activity and defensive pipeline context
In the derivatives market, trading in Bristol Myers Squibb has included notable hedging interest. As MarketBeat reported on September 10, 2026, investors recently purchased a large volume of put options on Bristol Myers Squibb, with the underlying NYSE BMY shares trading down USD 0.65 that day to USD 63.76, a sign that some market participants are positioning for downside or seeking protection even as the fundamental tone improves.
That defensive stance sits alongside a backdrop of active pipeline work. A company-focused note on clinical development from TipRanks on September 10, 2026 highlighted that Bristol Myers Squibb is targeting a pediatric multiple sclerosis edge with a new ozanimod study against fingolimod, with an update dated September 9, 2026 indicating that trial timelines and assumptions for ozanimod in multiple sclerosis remain in play, supporting the longer-term growth narrative beyond the near-term earnings guidance.
From a valuation-risk perspective, GuruFocus calculates a GF Value of USD 56.54 for Bristol Myers Squibb and notes that the stock’s recent price of USD 64.03 represents a 13.2 percent premium to that intrinsic-value estimate, characterizing the shares as overvalued by about 13.2 percent on this metric despite the solid fundamental profile.
Insider activity has also been modestly on the selling side, with the same GuruFocus snapshot pointing to a recent aggregate insider sell value of USD 33,750 over the preceding three months, a small figure in relation to a market capitalization above USD 130 billion, but still a data point that cautious investors may weigh alongside the options hedging flows.
Stock metrics around support and range
Looking at key trading metrics, Bristol Myers Squibb’s share price of USD 64.17 on the NYSE as of September 11, 2026, quoted around late morning Eastern time, compares with a 52-week range between USD 42.52 and USD 68.64, according to MarketBeat, placing the current level roughly USD 21.65 above the 52-week low and USD 4.47 below the 52-week high.
The same MarketBeat data show a market capitalization of USD 131.07 billion for Bristol Myers Squibb as of September 11, 2026, supported by a trailing twelve-month earnings per share figure of USD 4.54 and a dividend yield of about 3.93 percent, while the price-to-earnings ratio based on trailing earnings stands at 14.12, below many peers in the large-cap pharmaceutical universe.
From a performance standpoint, Zacks underscores that Bristol Myers Squibb has outperformed both its sector and the S&P 500 year to date, achieving a 19.4 percent gain in its shares against 6.3 percent growth for its industry, helped by a dividend yield of approximately 3.9 percent and incremental upgrades in earnings expectations.
Short-term trading, however, has been more volatile, with Yahoo Finance noting on September 10, 2026 that Bristol Myers Squibb fell 1.02 percent to USD 63.75 in the latest close, while the broader market also declined, and that shares had gained 1.11 percent over the preceding month, illustrating how the stock has been oscillating around the mid-USD 60s as investors balance earnings strength against valuation and pipeline risk.
Closing view on Bristol Myers Squibb stock
As of September 11, 2026, Bristol Myers Squibb stock trades on the NYSE at about USD 64.17 in USD, with the price sitting modestly below an average analyst target near USD 66.33 and within the upper third of its 52-week range between USD 42.52 and USD 68.64, a configuration that reflects solid earnings guidance and year-to-date outperformance but also embeds expectations that leave only limited quantified upside in the near term.
Bristol Myers Squibb stock snapshot
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 11, 2026, 11:59): 64.17 USD
- Market capitalization: 131.07 billion USD (as of September 11, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: S&P 500
